Reuters logo
BRIEF-Eleven Biotherapeutics to collaborate with Astrazeneca, National Cancer Institute
June 6, 2017 / 12:11 PM / in 6 months

BRIEF-Eleven Biotherapeutics to collaborate with Astrazeneca, National Cancer Institute

June 6 (Reuters) - Eleven Biotherapeutics Inc:

* Eleven Biotherapeutics to collaborate with Astrazeneca and National Cancer Institute on development of vicinium in combination with durvalumab

* Eleven Biotherapeutics Inc says vicinium is currently in a phase 3 registration trial for treatment of high-grade NMIBC

* Eleven Biotherapeutics - for phase 3 expects to complete patient enrollment in second half of 2017, and to report topline 3-month data in Q2 of 2018

* Says the combination drug is for treatment of non-muscle invasive bladder cancer Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below